Role of magnetic resonance spectroscopic imaging ([1H]MRSI) and dynamic contrast-enhanced MRI (DCE-MRI) in identifying prostate cancer foci in patients with negative biopsy and high levels of prostate-specific antigen (PSA)

Heidenreich A, Aus G, Bolla M et al (2008) EAU guidelines on prostate cancer. Eur Urol 53:68–80 Catalona WJ (1996) Clinical utility of measurement of free and total prostate specific antigen (PSA): a review. Prostate 7[suppl]: 64 Seitz M, Shukla-Dave A, Bjartell A et al (2009) Functional magnetic resonance imaging in prostate cancer. Eur Urol 55:801–814 Panebianco V, Sciarra A, Osimani M et al (2009) 2D and 3D T2-weighted MR sequence for the assessment of neurovascular bundles changes after nerve sparing radical prostatectomy with erectile function correlation. Eur Radiol 19:220–229 Kirkham AP, Emberton M, Allen C (2006) How good is MRI at detecting and characterising cancer within the prostate? Eur Urol 50:1163–1175 Carlani M, Mancino S, Bonanno E et al (2008) Combined morphological, [1H] spectrocopic and contrast enhanced imaging of human prostate cancer with a 3-Tesla scanner: preliminary experience. Radiol Med 113:670–688 Rajesh A, Coakley FV, Khrhanewicz J (2007) 3D spectroscopic imaging in the evaluation of prostate cancer. Clin Radiol 62:921–929 Hricak H (2005) MR imaging and MR spectroscopic imaging in the pretreatment evaluation of prostate cancer. Br J Radiol 78:103–111 Rajesh A, Coakley FV (2004) MR imaging and MR spectroscopic imaging of prostate cancer. Magn Reson Imaging Clin N Am 12:557–579 Manenti G, Squillaci E, Carlani M et al (2006) Magnetic resonance imaging of the prostate with spectroscopic imaging using a surface coil. Initial clinical experience. Radiol Med 111:22–32 Casciani E, Gualdi G (2006) Prostate cancer: value of magnetic resonance spectroscopy 3D chemical shift imaging Abdom Imaging 31:490–499 Sciarra A, Salciccia S, Panebianco V (2008) Proton spectroscopic and dynamic contrast-enhanced magnetic resonance: a modern approach in prostate cancer imaging. Eur Urol 54:485–488 Yuen JSP, Thng CH, Tan PH et al (2004) Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. J Urol 171:1482–1486 Amsellem-Ouazana D, Younes P, Conquy S et al (2005) Negative prostatic biopsies in patients with high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. Eur Urol 47:582–586 Zackrisson B, Aus G, Bergdahl S et al (2004) The risk of findings focal cancer (less than 3 mm) remains high on rebiopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable. J Urol 171:1500–1503 Sciarra A, Autran Gomez A, Salciccia S et al (2008) Biopsy-derived Gleason artifact and prostate volume: experience using ten samples in larger prostates. Urol Int 80:145–150 Kumar R, Nayyar R, Kumar V (2008) Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: a follow-up study. Urology 72:859–863 Wefer AE, Hricak H, Vigneron DB et al (2000) Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 164:400–404 Testa C, Schiavina R, Lodi R et al (2007) Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11-choline PET/CT. Radiology 244:797–806 Kurhanewicz J, Vigneron DB, Hricak H et al (1996) Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24–0.7-cm3) spatial resolution. Radiology 198:795–805 Cirillo S, Petracchini M, Della Monica P et al (2008) Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumors. Clin Radiol 63:871–879 Fütterer JJ, Heijmink SW, Scheenen TW et al (2006) Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 241:449–458 Wetter A, Hübner F, Lehnert T et al (2005) Three-dimensional 1H-magnetic resonance spectroscopy of the prostate in clinical practice: technique and results in patients with elevated prostatespecific antigen and negative or no previous prostate biopsies. Eur Radiol 15:645–652 Lawrentschuk N, Fleshner N (2009) The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU Int 103:730–733 Scattoni V, Zlotta A, Montironi R et al (2007) Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 52:1309–1322 Rabets JC, Jones JS, Patel A Zippe CD (2004) Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. J Urol 172:94–97 Perrotti M, Han KR, Epstein RE et al (1999) Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostatic biopsy: a pilot study. J Urol 162:1314–1322 Vilanova JC, Comet J, Capdevila A et al (2001) The value of endorectal MR imaging to predict positive biopsies in clinically intermadiate-risk prostate cancer patients. Eur Radiol 11:229–235